Restrizymes Biotherapeutics (U) LTD Africa's leading biotech company for new diagnostics, drugs and vaccines

We are a start up biotech focused on meeting the need for new diagnostics, therapeutics and or vaccines against infectious , rare genetic and immune diseasess that preferentially affect the people(s) of sub-Saharan Africa. We use genomics and related technologies to unveil molecular targets for the development of the next generation of interventions. Our most successful advanced prototypes include (i) a rapid diagnostic test (RDT) for ebola virus disease-EVD, (ii) HIV-1 gene therapy, (iii) TB LFT and Microfluidics rapid culture systems. With over 10 new molecular entities-NMEs in the offing, we aim to build a company net-worth of US$6-12 billion (premised on the market price of each NME of between US$600-to $1.2 billion)

Sectores Biotecnología e investigación médica, Productos farmacéuticos
Ubicación Uganda
Etapa Inicie la sesión para ver los detalles
Mercados Inicie la sesión para ver los detalles
Contacto Inicie la sesión para ver los detalles
Medios sociales